TrialJAMA oncology2025

Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

Xingming Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.